Bracco: Prostatic Neoplasms trials

The registry lists 13 Prostatic Neoplasms studies with Bracco as lead sponsor. 2 are open to participants now and 8 have results posted.

Early Phase 1 2Phase 1 3Phase 2 2Phase 3 5Phase 4 2No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical RecurrenceRecruitingNCT07569926Phase 4
• Anti-tumour Activity of (177Lu) rhPSMA-10.1 InjectionRecruitingNCT05413850Phase 1/2
• Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical ProstatectomyCompletedNCT06604442Phase 4Results posted
• Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer RecurrenceCompletedNCT04186845Phase 3Results posted
• Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.CompletedNCT04186819Phase 3Results posted
• Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate CancerCompletedNCT03995888Phase 1Results posted
• 18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer TreatmentCompletedNCT02680041Phase 3Results posted
• Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcerCompletedNCT02578940Phase 3Results posted
• Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC)CompletedNCT02443571Results posted
• A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate CancerCompletedNCT02142608Phase 1/2Results posted
• A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate CancerTerminatedNCT06516510Early Phase 1
• BR55 in Prostate Cancer: an Exploratory Clinical TrialCompletedNCT01253213Early Phase 1
• SonoVue Guided Prostate BiopsyTerminatedNCT00911027Phase 3